Probenecid
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1951
- First approval year
- 1951
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Probenecid
- Molecular weight
- 285.37
- Structure (SMILES)
- CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
- benemid
- Benemid
- benuryl
- Benuryl
- probalan
- Probalan
- probampicin
- Probampicin
- probecid
- Probecid
- probenecid
- Probenecid
- probenecid component of col
- Probenecid component of col-
- probenecid component of colbenemid
- Probenecid component of colbenemid
- probenecid component of orlynvah
- Probenecid component of orlynvah
- probenecid component of probampacin
- Probenecid component of probampacin
- probenecid component of proben c
- Probenecid component of proben-c
- benzoic acid 4 dipropylamino sulfonyl
- BENZOIC ACID, 4-((DIPROPYLAMINO)SULFONYL)-
- col probenecid component probenecid
- COL-PROBENECID COMPONENT PROBENECID
- colbenemid component probenecid
- COLBENEMID COMPONENT PROBENECID
- hc 5006
- HC 5006
- nsc 18786
- NSC-18786
- orlynvah component probenecid
- ORLYNVAH COMPONENT PROBENECID
- p dipropylsulfamoyl benzoic acid
- P-(dipropylsulfamoyl)benzoic acid
- probampacin component probenecid
- PROBAMPACIN COMPONENT PROBENECID
- probecid
- proben c component probenecid
- PROBEN-C COMPONENT PROBENECID
- probenate
- Probenate
- probenecid
- Probenecid
- PROBENECID [EP IMPURITY]
- PROBENECID [EP MONOGRAPH]
And 30 more, listed on the interactive page.
- ATC classification codes
- M04AB01
Sources for recorded values
- CAS registry numbers
- 57-66-9
- ChEMBL ID
- CHEMBL897
- InChIKey
- DBABZHXKTCFAPX-UHFFFAOYSA-N
- PubChem compound IDs
- 4911
- RxNorm IDs (RxCUI)
- 8698
- FDA ingredient codes (UNII)
- PO572Z7917
- Applicant
- ITERUM THERAP
- Approval date
- 25 Oct 2024
- Application number
- NDA213972
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- probenecid
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- TAS2R38
- Gene symbol
- TAS2R38
- Protein identifier
- P59533
- Median affinity
- 3.68
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- TAS2R16
- Gene symbol
- TAS2R16
- Protein identifier
- Q9NYV7
- Median affinity
- 3.53
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Organic anion transporter 1
- Gene symbol
- SLC22A6
- Protein identifier
- Q4U2R8
- Median affinity
- 4.9
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- OATP1C1
- Gene symbol
- SLCO1C1
- Protein identifier
- Q9NYB5
- Mechanism
- Solute carrier family 22 member 11 inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 22 member 11
- Protein identifier
- Q9NSA0
- Mechanism
- Solute carrier family 22 member 6 inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 22 member 6
- Protein identifier
- Q4U2R8
- Mechanism
- Solute carrier family 22 member 8 inhibitor
- Action type
- Inhibitor
- Target
- Organic anion transporter 3
- Protein identifier
- Q8TCC7
- Mechanism
- Solute carrier family 22 member 11 inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 22 member 11
- Mechanism
- Solute carrier family 22 member 6 inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 22 member 6
- Mechanism
- Solute carrier family 22 member 8 inhibitor
- Action type
- Inhibitor
- Target
- Organic anion transporter 3
- Action type
- Inhibitor
- Gene symbol
- SLC22A6
- Protein identifier
- Q4U2R8
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- SLC22A8
- Protein identifier
- Q8TCC7
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- SLC22A11
- Protein identifier
- Q9NSA0
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Obesity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Cellulitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003035
- Subject identifier
- D002481
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Heart Failure
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Infertility, Male
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004248
- Subject identifier
- D007248
- Condition
- Gout
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004274
- Subject identifier
- D006073
- Condition
- Influenza in Birds
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005222
- Subject identifier
- D005585
- Condition
- Cystitis, Hemorrhagic
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000025
- Subject identifier
- D000096722
- Condition
- Heart Failure, Systolic
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001207
- Subject identifier
- D054143
- Condition
- Chondrocalcinosis
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0001314
- Subject identifier
- D002805
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Alcoholism
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007079
- Subject identifier
- D000437
- Condition
- Brain Injuries
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0043510
- Subject identifier
- D001930
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003103
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003144
- Condition identifier
- EFO_0004248
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004263
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004274
- Condition identifier
- EFO_0004329
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000025
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001207
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001461
- Highest recorded phase
- 3
- Condition identifier
- HP_0000789
- Highest recorded phase
- 3
- Condition identifier
- HP_0000822
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000496
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000878
- Condition identifier
- MONDO_0001314
- Condition identifier
- MONDO_0001314
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002046
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005230
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005393
- Highest recorded phase
- 4
And 4 more, listed on the interactive page.
- Event
- asthenospermia
- Reports
- 1
- Reporting signal score
- 6.10191
- Event
- calcinosis
- Reports
- 3
- Reporting signal score
- 13.604
- Event
- chronic kidney disease
- Reports
- 3
- Reporting signal score
- 6.13636
- Event
- clostridium colitis
- Reports
- 2
- Reporting signal score
- 8.53841
- Event
- desmoid tumour
- Reports
- 2
- Reporting signal score
- 12.0105
- Event
- diarrhoea
- Reports
- 15
- Reporting signal score
- 11.1094
- Event
- drug interaction
- Reports
- 11
- Reporting signal score
- 13.9831
- Event
- drug intolerance
- Reports
- 8
- Reporting signal score
- 12.55
- Event
- eosinophil morphology abnormal
- Reports
- 1
- Reporting signal score
- 7.89299
- Event
- fahr's disease
- Reports
- 1
- Reporting signal score
- 7.19998
- Event
- hepatitis toxic
- Reports
- 3
- Reporting signal score
- 11.4359
- Event
- hepatotoxicity
- Reports
- 4
- Reporting signal score
- 8.94733
- Event
- hyperchromic anaemia
- Reports
- 2
- Reporting signal score
- 13.1724
- Event
- hyperemesis gravidarum
- Reports
- 2
- Reporting signal score
- 10.7707
- Event
- hypozincaemia
- Reports
- 1
- Reporting signal score
- 6.84342
- Event
- infertility
- Reports
- 3
- Reporting signal score
- 14.6248
- Event
- international normalised ratio abnormal
- Reports
- 2
- Reporting signal score
- 6.16628
- Event
- jarisch-herxheimer reaction
- Reports
- 2
- Reporting signal score
- 8.90888
- Event
- leukocytosis
- Reports
- 6
- Reporting signal score
- 16.2438
- Event
- leukopenia neonatal
- Reports
- 1
- Reporting signal score
- 6.25595
- Event
- lymphocytopenia neonatal
- Reports
- 1
- Reporting signal score
- 6.94874
- Event
- microvillous inclusion disease
- Reports
- 1
- Reporting signal score
- 6.54345
- Event
- multiple organ dysfunction syndrome
- Reports
- 4
- Reporting signal score
- 14.193
- Event
- muscular weakness
- Reports
- 5
- Reporting signal score
- 6.2278
- Event
- myopathy
- Reports
- 10
- Reporting signal score
- 38.9817
And 11 more, listed on the interactive page.
- NCT00024245
- NCT00439530
- NCT00842400
- NCT01320722
- NCT01029782
- NCT01322009
- NCT01814319
- NCT02243631
- NCT03296800
- NCT03466567
- NCT05497674
- NCT03354598
- NCT03357614
- NCT05584657
- NCT03358576
- NCT05082909
- NCT04218357
- NCT04551222
- NCT05618314
- NCT05903859
- Dose
- 500 mg
- Route
- Oral
- How often
- Twice daily
Conditions of use
- Take with food
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 74.68
- Calculated partition coefficient (ALogP)
- 2.2
- Calculated partition coefficient (XLogP)
- 3.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 19
- Molecular formula
- C13H19NO4S
- Monoisotopic mass
- 285.10347926
- Natural product
- Yes
- 0527-1367
- 0591-5325
- 0591-5347
- 10135-541
- 16571-831
- 16571-832
- 50742-263
- 81153-100
- 70518-4644
- 70518-4649
- 72162-2237
- 72162-2386
- Recorded assays
- 3,928
- Active assays
- 52
- Confirmatory
- Other
- Summary
- Adjuvants, Pharmaceutic
- Uricosuric Agents
Distribution coefficient (LogD)
- Median
- 0.11
- Mean
- 0.11
- Minimum
- 0.11
- Maximum
- 0.11
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Solubility
- Median
- 3.9
- Mean
- 3.9
- Minimum
- 3.9
- Maximum
- 3.9
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Plasma protein binding
- Median
- 83
- Mean
- 83
- Minimum
- 83
- Maximum
- 83
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (61)
- 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
- A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
- A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
- A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults
- A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
- A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
- A Study of Baricitinib and Probenecid in Healthy Participants
- A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
- A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants
- A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
- A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects
- A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
- A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
- A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Addition of Probenecid to Penicillin-V Therapy
- An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
- Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers
- AV-101 Alone and in Combination With Probenecid in Healthy Subjects
Approved for (1)
In development for (17)
- Alcohol dependence Phase 1
- Avian influenza Phase 1
- Brain injury Phase 1
- Cellulitis Phase 2
- Chondrocalcinosis Early phase 1
- COVID-19 Phase 2
- Cystitis Phase 3
- Diabetes mellitus Phase 1
- Focal epilepsy Phase 2
- Heart failure Phase 2
- Kidney disorder Phase 1
- Male infertility Phase 3
- Neoplasm Phase 1
- Obesity disorder Phase 3
- Systolic heart failure Phase 2
- Type 2 diabetes mellitus Phase 1
- Urinary tract infection Phase 3